ORYZF (Oryzon Genomics) Payments of Debt: $0.00 Mil (TTM As of Mar. 2026)


ORYZF Oryzon Genomics SA ORYZF
31 GF Score
Price $3.66
View Full Analysis

What is Oryzon Genomics Payments of Debt?

Oryzon Genomics ORYZF 31 Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates ORYZF with a GF Score™ of 31/100.

Oryzon Genomics's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Oryzon Genomics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Oryzon Genomics Payments of Debt Related Terms

Oryzon Genomics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Payments of Debt Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.35 -4.75 -8.42 -15.77 -13.36

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ORYZF
31GF Score
Oryzon Genomics SA ORYZF
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Oryzon Genomics (ORYZF) has a Payments of Debt of $0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Payments of Debt too high?
Oryzon Genomics' current Payments of Debt is $0.00 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Payments of Debt compare to VRTX and REGN?
Oryzon Genomics' Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for ORYZF

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price